drugset / Trial / NCT03103334

A Bioavailability Study of Methotrexate 25 mg Administered by Needle Injection and a Pre Filled Needle-free Device in Healthy Volunteers.

NCT03103334

Phase 1 Completed 58 enrolled Crossject
RandomizedCrossoverOpen-labelTreatment

Summary

The objective is to determine whether the test product, Methotrexate 40 mg/mL solution for injection administered subcutaneously by the prefilled and needle-free delivery system Zeneo®, and the reference product, Methotrexate Biodim® 25 mg/mL, solution for injection administered subcutaneously by a conventional syringe with needle are bioequivalent.

Timeline

Start
2014-06
Primary completion
2014-09
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule 25 mg Subcutaneous

Indications

No indication recorded.